VIVA IN VITRO DIAGNOSTICS, S.L.

VIVA In Vitro Diagnostics, S.L. is a Spanish biotechnology company that aims to revolutionise immunological medicine through new pioneering advances in the diagnosis, prognosis and early stratification of patients with sepsis. The company was founded in 2021 as a spin-off of the IMIB (Murcia Institute for Biomedical Research), with the mission of transforming research into immune diseases and saving lives, bringing science to clinical application and to patients. Their research into sepsis has led them to develop VIVA-ELISA®, an advanced diagnostic technology based on the activation of the NLRP3 inflammasome through the detection of ASC-Speck, which allows for the early identification and screening of critically septic patients in an easier and faster way.

Viva in Vitro has become an international biomedical benchmark and has been chosen as one of the most disruptive companies in the sector according to the European Innovation Council of the European Commission. This recognition has allowed it to be one of the 40 European companies selected to enter the prestigious EIC Transition programme (April 2025), within the Horizon Europe 2020-2027 programme.

Its mission is to anticipate the consequences of a condition such as sepsis, where every hour counts for millions of patients worldwide. Its team has developed reliable and easy-to-use tools that allow doctors to stratify patients by their immune status, severity and prognosis hours in advance compared to current methods, facilitating the personalisation of their treatment and improving the use of very valuable resources in ICUs and emergency rooms.

The company is developing, under ISO 13485 standards, a range of products for the rapid and accurate detection of NLRP3, which will initially be launched under the VIVA ELISA® brand, a high-sensitivity immunoassay designed as a classic quantitative sandwich ELISA. The product forecast is as follows:
1.- VIVA ELISA® RUO, (Research Use Only | Launch Q4 2025). High sensitivity ELISA kit for basic research and pharmaceutical development
2.- VIVA ELISA® Clinica, (FDA/CE certification expected | Launch 2028). First clinical ELISA for monitoring NLRP3-dependent diseases
3.- VIVA SEPS CARE®, an automatic random access device for mass use in hospitals and clinical laboratories (currently under evaluation).